Ying-Bei Chen Selected Research

Leiomyomatosis

1/2021	Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma.
1/2021	New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.
12/2018	Clues to recognition of fumarate hydratase-deficient renal cell carcinoma: Findings from cytologic and limited biopsy samples.
1/2018	Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma.
10/2017	Leiomyoma with bizarre nuclei: a morphological, immunohistochemical and molecular analysis of 31 cases.
7/2017	A distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma, morphologically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma.
11/2016	Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci: A Frequent Morphologic Pattern of Fumarate Hydratase-deficient Renal Cell Carcinoma.
7/2014	Uterine smooth muscle tumors with features suggesting fumarate hydratase aberration: detailed morphologic analysis and correlation with S-(2-succino)-cysteine immunohistochemistry.
5/2014	Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ying-Bei Chen Research Topics

Disease

47	Neoplasms (Cancer) 10/2022 - 12/2010
28	Renal Cell Carcinoma (Grawitz Tumor) 09/2022 - 05/2013
9	Leiomyomatosis 01/2021 - 05/2014
8	Kidney Neoplasms (Kidney Cancer) 09/2022 - 04/2014
8	Carcinoma (Carcinomatosis) 01/2022 - 12/2010
6	Prostatic Neoplasms (Prostate Cancer) 01/2020 - 12/2010
4	Disease Progression 01/2021 - 12/2010
3	Leiomyoma (Uterine Fibroids) 10/2017 - 05/2014
2	Margins of Excision 01/2022 - 01/2019
2	Neoplasm Metastasis (Metastasis) 01/2021 - 04/2014
2	Hereditary leiomyomatosis and renal cell cancer 01/2020 - 01/2019
2	Adenocarcinoma 01/2020 - 01/2018
2	Medullary Carcinoma 01/2019 - 01/2018
2	Sickle Cell Trait 01/2019 - 01/2017
1	Inflammation (Inflammations) 10/2022
1	Small Cell Carcinoma 10/2022
1	Urachal adenocarcinoma 01/2022
1	Rare Diseases (Rare Disease) 01/2022
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2022
1	Urogenital Neoplasms 05/2021
1	Extramammary Paget Disease (Paget Disease, Extramammary) 01/2021
1	Microsatellite Instability 01/2021
1	Turcot syndrome 01/2019
1	Urinary Bladder Neoplasms (Bladder Cancer) 01/2019
1	Hepatocellular Carcinoma (Hepatoma) 01/2019
1	Lymphatic Metastasis 01/2019
1	Genetic Predisposition to Disease (Genetic Predisposition) 01/2019
1	Hemoglobinopathies 01/2018
1	Trisomy (Trisomies) 02/2016
1	sporadic Papillary renal cell carcinoma 01/2016
1	Papillary Carcinoma 06/2015

Drug/Important Bio-Agent (IBA)

17	Fumarate Hydratase (Fumarase)IBA 09/2022 - 04/2014
8	Proteins (Proteins, Gene)FDA Link 09/2022 - 04/2014
8	DNA (Deoxyribonucleic Acid)IBA 06/2021 - 12/2010
6	Biomarkers (Surrogate Marker)IBA 10/2022 - 05/2013
6	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2019
5	Everolimus FDA Link 12/2020 - 11/2016
4	RNA (Ribonucleic Acid)IBA 01/2022 - 12/2018
3	Succinate Dehydrogenase (Fumarate Reductase)IBA 09/2022 - 07/2017
3	EnzymesIBA 09/2022 - 04/2014
3	NivolumabIBA 01/2022 - 01/2021
3	Biological ProductsIBA 11/2019 - 01/2017
3	TOR Serine-Threonine KinasesIBA 01/2019 - 12/2010
3	ChromatinIBA 01/2019 - 12/2010
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019 - 01/2017
2	FumaratesIBA 09/2022 - 05/2014
2	Prostate-Specific Antigen (Semenogelase)IBA 01/2022 - 01/2019
2	Bevacizumab (Avastin)FDA Link 12/2020 - 11/2016
2	Androgen Receptors (Androgen Receptor)IBA 01/2020 - 12/2010
2	MART-1 AntigenIBA 11/2019 - 11/2017
2	Messenger RNA (mRNA)IBA 11/2019 - 01/2016
2	SMARCB1 ProteinIBA 01/2019 - 12/2017
2	AntibodiesIBA 01/2019 - 05/2013
2	Sunitinib (Sutent)FDA Link 12/2017 - 01/2017
1	Adenosine A2A Receptor (Adenosine A2A Receptors)IBA 10/2022
1	CitrullineIBA 09/2022
1	Furylfuramide (AF2)IBA 09/2022
1	Urea (Carbamide)FDA LinkGeneric 09/2022
1	LigandsIBA 01/2022
1	cabozantinibIBA 01/2022
1	Small Cytoplasmic RNAIBA 10/2021
1	B7-H1 AntigenIBA 01/2021
1	Anaplastic Lymphoma KinaseIBA 01/2021
1	IpilimumabIBA 01/2021
1	Cathepsin KIBA 11/2019
1	Checkpoint Kinase 2IBA 01/2019
1	temsirolimus FDA Link 01/2019
1	TensinsIBA 01/2019
1	Mitochondrial DNA (mtDNA)IBA 01/2019
1	GlycogenIBA 01/2019
1	LipidsIBA 01/2019
1	NucleotidesIBA 01/2019
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2019
1	Sorbitol (Yal)FDA Link 01/2019
1	Sucrose (Saccharose)IBA 01/2019
1	Sugar AlcoholsIBA 01/2019
1	HoloenzymesIBA 01/2019
1	Neurofibromin 2 (Merlin)IBA 01/2019
1	chenodeoxycholate sulfate conjugate (CDCS)IBA 01/2018
1	Pharmaceutical PreparationsIBA 12/2017
1	Transcription Factors (Transcription Factor)IBA 11/2017
1	Glucose (Dextrose)FDA LinkGeneric 11/2017
1	Lactic Acid (Lactate)FDA LinkGeneric 11/2017
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 11/2017
1	Oxygen (Dioxygen)IBA 11/2017
1	alpha-methylacyl-CoA racemaseIBA 02/2016
1	MicroRNAs (MicroRNA)IBA 01/2016
1	Phenobarbital (Luminal)FDA Link 06/2015
1	Carbonic Anhydrase IXIBA 06/2015

Therapy/Procedure

23	Therapeutics 10/2022 - 05/2013
6	Nephrectomy 01/2022 - 10/2013
6	Prostatectomy (Retropubic Prostatectomy) 01/2022 - 01/2018
3	Immunotherapy 01/2022 - 01/2019
2	Cystectomy 10/2022 - 12/2010
2	Neoadjuvant Therapy 10/2022 - 01/2022
2	Drug Therapy (Chemotherapy) 10/2022 - 01/2021
1	Chemoradiotherapy 10/2022
1	Adjuvant Chemotherapy 10/2022
1	Precision Medicine 10/2018
1	Exercise Therapy (Therapy, Exercise) 01/2015